Use of haemopoietic growth factors: Commentary on the ASCO/ECOG guidelines

Blood Reviews

Volumn 11, Issue 1, 1997, Pages 16-27

  Byrne, J L ^a   Haynes, A P ^a   Russell, N H ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

ARTICLE; GOOD CLINICAL PRACTICE; HUMAN; LEUKEMIA; LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; TRANSPLANTATION; UNITED KINGDOM;

EID: 0030913069     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90003-5     Document Type: Article

References (83)

1. ASCO. American Society of Clinical Oncology Recommendations for the use of Hematopoietic Colony-Stimulating Factors: Evidence-based Clinical Practice Guidelines. J Clin Oncol 1994; 12(11): 2471-2508.
2. Rowe JM, Ciobanu N, Ascensao J et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. Ann Intern Med 1994; 120(2): 143-157.
3. ASCO. Update of Recommendations for the use of Hematopoietic Colony-Stimulating Factors: Evidence-Based Clinical Practice Guidelines. J Clin Oncol 1996; 14(6): 1957-1960.
4. Meyer RM, Browman GP, Samosh ML et al. Randomised phase II comparison of standard CHOP with weekly CHOP in elderly patients with NHL. J Clin Oncol 1995; 13: 2386.
5. Pettengell R, Gurney H, Radford GA et al. G-CSF to prevent dose limiting neutropenia in NHL: a randomised controlled trial. Blood 1992; 80(6): 1430-1436.
6. Meher DW, Lieschke GJ, Green M et al. Filgrastim in patients with chemotherapy induced febrile neutropenia: a double blind controlled trial. Ann Intern Med 1994; 121: 492.
7. Gerhartz HH, Engelhaed M, Meusers P et al. A randomised, double blind placebo controlled phase III study of rh GM-CSF as adjunct to induction treatment of high grade NHL. Blood 1993; 82: 2329-2339.
8. Gisselbrecht C. Critical Review II - What do growth factors contribute to dose intensity and outcome in the treatment of NHL? Proc. 5th Int. Conf. On Malignant Lymphoma 1993: 32a.
9. Tesch H, Lathan B, Fruffer LI et al. Escalation of dose intensity for advanced stage Hodgkin's disease using the BEACOPP scheme - studies of the German Hodgkin's Study Group. Blood 1996; 10(SI): 675a.
10. Lowenberg B, Touw IP. Hemopoietic growth factors and their receptors in acute leukaemia. Blood 1993; 81: 281.
11. Koistinen P, Wang G, Curtis JE et al. Granulocyte-macrophage colony-stimulating factor and interleukin - 3 protect leukaemic blast cells from Ara-C toxicity. Leukemia 1991; 5: 789-795.
12. Stone RM, Berg DT, George SL et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia. N Engl J Med 1995; 332: 1671-1677.
13. Heil G, Hoelzer D, Sanz MA et al. Results of a randomised double-blind placebo controlled trial of filgrastim in remission induction and early consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1995; 86(suppl. 1): 267a.
14. Dombret H, Chastang C, Fenaux P et al. A controlled study of recombinant granulocyte-colony stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995; 332: 1678-1683.
15. Rowe JM, Anderson JW, Mazza JJ et al. A randomised placebo-controlled phase III trial of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
16. Schiffer CA. Hemopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996; 88: 3675-3685.
17. Zittoun R, Sucio S, Mandelli F et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomised trial by the European Organisation for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996; 14: 2150-2159.
18. Lowenberg B, Sucio S, Zittoun R et al. GM-CSF during as well as after induction chemotherapy in elderly patients with acute myeloid leukemia. The EORTC-HOVON phase III trial (AML-11). Blood 1995; 86: 433a.
19. Ohno R, Naoe T, Kanamaru A et al. A double blind controlled study of granulocyte colony-stimulating factor started 2 days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994; 83: 2086-2092.
20. Lotem J, Sachs L. Control of apoptosis in haemopoiesis and leukaemia by cytokines, tumour suppressor genes and oncogenes. Leukemia 1996; 10: 925-931.
21. Kaplinsky C, Lotem J, Sachs L. Protection of tumour myeloid leukemic cells against doxorubicin induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin-3. Leukemia 1996; 10: 460-465.
22. Bradbury D, Zhu Y-M, Russell NH. Regulation of bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia 1994; 8: 786-791.
23. Linch D, Scarffe H, Proctor S et al. A randomised vehicle controlled dose finding study of glycosylated recombinant human G-CSF after bone marrow transplantation. Bone Marrow Transplant 1993; 11: 307-311.
24. Gisselbrecht C, Prentice HG, Bacigalupo A et al. Placebo controlled phase III trial of lenograstim in bone marrow transplantation. Lancet 1994; 343: 696-700.
25. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, MacDonald JS. Granulocyte colony-stimulating accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13(6): 1323-1327.
26. Linch DC, Milligan DW Winfield DA et al. G-CSF significantly accelerates neutrophil recovery after peripheral blood stem cell transplantation (PBSCT) in lymphoma patients and shortens the time in hospital; preliminary results of a randomised trial. Blood 1995; 86(S1): 873.
27. Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral blood stem-cell transplantation: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12(4): 661-670.
28. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral blood stem cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Pathol 1997; 15: 451-457.
29. Calderwood S, Doyle J, Hitzler K et al. Administration of recombinant human granulocyte-macrophage-colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukaemia: a note of caution. Bone Marrow Transplant 1996; 18: 87-91.
30. Kwaja A, Mills W, Leveridge K et al. Efficacy of delayed G-CSF after autologous bone marrow transplantation. Bone Marrow Transplant 1993; 11: 479-482.
31. Faucher C, Lecorroller A, Chabannon C et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem-cells - a randomized study. Bone Marrow Transplant 1996; 17(4): 533-536.
32. Schimazaki C, Oku N, Uchiyama N et al. Effect of granulocyte-colony stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1994; 13: 271-275.
33. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte-colony-stimulating factor). Blood 1995; 85(6): 1666-1672.
34. Masoaka T, Takaku F, Kato S et al. Recombinant human G-CSF in allogeneic bone marrow transplantation. Exp Haematol 1989; 17: 1047-1050.
35. Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase II randomised double blind placebo controlled trial of RhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949-954.
36. Locatelli F, Pession A, Zecca M et al. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukaemia. Bone Marrow Transplant 1996; 17: 31-37.
37. Schmitz N, Bacigalupo A, Labopin M et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. Br J Haematol 1986; 95: 715-723.
38. Urbano-Ispizua A, Solano C, Brunet S et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of short term engraftment and acute GVDHD incidence in 33 cases. Bone Marrow Transplant 1996; 18: 35-40.
39. Nemunaitis J, Anasetti C, Storb R et al. Phase II trial of recombinant human GM-CSF in patients undergoing allogeneic bone marrow transplant from unrelated donors. Blood 1992; 79(10): 2572-2577.
40. Atkinson K, Rowlings PA, Pelz CJ, Horowitz MM, IBMTR. Effects of G- and GM-CSF on outcomes following HLA-identical sibling bone marrow transplants for early leukaemia. Blood 1996; 88(10)S1: 2449.
41. Keil F, Kalhs P, Haas O et al. G-CSF stimulation of donor myelopoiesis prolongs survival of relapsed BCR-ABL-positive acute lymphoblastic leukaemia after allogeneic marrow transplantation. Bone Marrow Transplant 1996; 18: 655-657.
42. Giralt S, Escudier S, Kantarajian H et al. Preliminary results of treatment with filgrastim for relapse of leukaemia and myelodysplasia after allogeneic transplantation. N Engl J Med 1993; 329: 757-761.
43. Weisdorf D, Verfaillie C, Davies S et al. Hematopoietic growth-factors for graft failure after bone-marrow transplantation - a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood 1995; 85(12): 3452-3456.
44. Nemuniatis J, Buckner CD, Singer JW et al. Use of recombinant GM-CSF in graft failure after bone marrow transplantation. Blood 1990; 76: 245-253.
45. Brandwein JM, Nayar R, Baker MA et al. GM-CSF therapy for delayed engraftment after autologous bone marrow transplant. Exp Haematol 1991; 19: 191-195.
46. Vose JM, Bierman, Kessinger A et al. The use of recombinant human granulocyte-colony-stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hemopoietic stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 1991; 7: 139-143.
47. Ippoliti C, Przepiorka D, Giralt S et al. Low dose non-glycosylated rhG-CSF is effective for the treatment of delayed hematopoietic recovery after autologous or peripheral blood stem cell transplantation. Bone Marrow Transplant 1993; 11: 55-59.
48. Reiffers J, Bernard P, David B et al. Successful autologous transplantation with peripheral blood haemopoietic cells in a patient with acute leukaemia. Exp Haematol 1986; 14: 312-315.
49. Kessinger A, Armitage J, Landmark J, Wesenberger D. Reconstitution of human haemopoietic function with autologous cryopreserved circulating stem cells. Exp Haematol 1986; 14: 192-196.
50. Schmitz N, Linch DC, Dreger P et al. A randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 3563-357.
51. Gratwohl A, Hermans J, Baldomero H. Haemopoietic precursor cell transplants in Europe - activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 137-148.
52. Kessinger HH, Armitage JO, Smither DM et al. High dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260-1265.
53. Juttner CA, To LB, Ho LQK et al. Early lymphohaemopoietic recovery after autografting using peripheral blood stem cells in acute lymphoblastic leukaemia. Transplant Proc 1989; 20: 40-42.
54. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor compartment in man. Lancet 1988; 1: 1194-1198.
55. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant granulocyte colony stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-2081.
56. Haynes A, Hunter A, McQuaker G, Anderson S, Bienz N, Russell NH. Engraftment characteristics of peripheral-blood stem-cells mobilized with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995; 16(3): 359-363.
57. Mavroudis D, Read E, Cottlerfox M et al. CD34(+) cell dose predicts survival, post-transplant morbidity and rate of haematological recovery after marrow transplants for haematological malignancy. Blood 1996; 88(8): 3223-3229.
58. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13(10): 2547-2555.
59. Gianni AM, Siena S, Bregni M et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-585.
60. Pettengell R, Testa NG, Swindell R, Crowther D, Dexter TM. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993; 82(7): 2239-2248.
61. Jones HM, Jones SA, Watts MJ et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12(8): 1693-1702.
62. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-697.
63. Demirer T, Buckner C, Bensinger W. Optimization of peripheral blood stem-cell mobilization. Stem Cells 1996; 14(1): 106-116.
64. McQuaker G, Haynes AP, Stainer C, Anderson S, Russell NH. Stem cell mobilisation in resistant or relapsed lymphoma - superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate dose cyclophosphamide. Br J Haematol 1997 (in press).
65. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83(12): 3787-3794.
66. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSC) collected after recombinant granulocyte colony stimulating factor (rhG-CSF), analysis of factors correlating with engraftment after transplant. Br J Haematol 1994; 87: 825-831.
67. Russell NH, Hunter A, Rogers S, Hanley J, Anderson D. Peripheral-blood stem-cells as an alternative to marrow for allogeneic transplantation. Lancet 1993; 341: 1482 (letter).
68. Weaver CH, Buckner CD, Longin K et al. Syngeneic transplantation with peripheral blood mononuclear sells collected after the administration of recombinant human granulocyte colony stimulating factor. Blood 1993; 82: 1982-1984.
69. Korbling M, Przepiorka D, Huh Y et al. Allogeneic blood stem cell transplantation for refractory leukaemia and lymphoma: potential advantages of blood over marrow allograft. Blood 1995; 85: 1659-1655.
70. Bensinger WI, Weaver C, Appelbaum F et al. Transplantation of allogeneic peripheral blood stem cells mobilised by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
71. Sakamaki S, Matsunaga T, Hirayama Y, Kuga T, Niitsu Y. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995; 346: 1432-1433 (letter).
72. Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
73. Matsunaga T, Sakamaki S, Kohgo Y, Ohi S, Hirayana Y, Niitsu Y. Recombinant human granulocyte colony-stimulating factor can mobilise sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 1993: 11: 103-108.
74. Dreger P, Haferlach T, Eckstein V et al. G-CSF-mobilised peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilisation, and composition of graft. Br J Haematol 1994; 87: 609-613.
75. Miflin G, Charley C, Stainer C, Anderson S, Hunter A, Russell NH. Stem cell mobilisation in normal donors for allogeneic transplantation: analysis of factors affecting efficacy. Br J Haematol 1996 95: 345-348.
76. Miflin G, Russell NH, Hutchinson RM et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - an analysis of engraftment and GVHD risk. Bone Marrow Transplant 1997; 19: 9-13.
77. Korbling M, Chan KW, Anderlini P et al. Allogeneic peripheral blood transplantation using normal patient related pediatric donors. Bone Marrow Transplant 1997 (submitted).
78. Roberts AW, DeLuca E, Begley CG, Basser R, Grigg AP, Metcalf D. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995; 13: 512.
79. Advani R, Chao NJ, Horning SJ et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation. Ann Int Med 1992; 116: 183-189.
80. Link H, Boogaerts MA, Carella MA et al. A controlled trial of recombinant human GM-CSF after total body irradiation, high dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukaemia and lymphoma. Blood 1992; 86(9): 2188-2195.
81. Gorin NC, Coiffier B, Hayat M et al. Recombinant human GM-CSF after high dose therapy and autologous bone marrow transplantation with unpurged and purged marrow in non Hodgkin's lymphoma: a double blind, placebo controlled trial. Blood 1992; 80(5): 1149-1157.
82. Rabinowe SN, Neuberg D, Bierman PJ et al. Long term follow up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993; 81: 1903-1908.
83. Stahel RA, Muller E, Pichert G et al. Dose intensification with autologous marrow support in high risk lymphoma: acceleration of hematopoietic recovery and reduction of days of hospitalisation with granulocyte colony-stimulating factor (G-CSF) in a randomised open-label trial. Proc Am Soc Clin Onc 1992; 11: 331a.